Please go to the PowerPak homepage
and select a course.
Cardiovascular Outcome Trials (CVOTs): Practical Considerations for your Type 2 Diabetes Patients
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Boehringer Ingelheim Pharmaceuticals Inc. and Lilly USA, LLC.
Curtis Triplitt, PharmD, CDE
Texas Diabetes Institute, University Health System
Associate Professor of Medicine, Clinical /Div. of Diabetes
University of Texas Health Science Center at San Antonio
San Antonio, TX
Joshua J. Neumiller, PharmD, CDE, FASCP
Department of Pharmacotherapy
Washington State University
Curtis Triplitt, PharmD, CDE discloses the following financial relationships or relationships to products or devices with a commercial interest related to the content of this activity: Speaker’s Bureau: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen
Consultant: Novo Nodisk and Sanofi US
Joshua J. Neumiller, PharmD, CDE, FASCP discloses the following financial relationships or relationships to products or devices with a commercial interest related to the content of this activity: receives grant/research support from AstraZeneca, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk; consultant for Eli Lilly and Sanofi US; a member of the speakers bureau for Novo Nordisk.
The following reviewer, Tricia Russell, PharmD, BCPS, CDE, hereby states that she does not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Susanne Batesko, RN, BSN, Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 1.0 hour (0.10 ceu)
Published: April 5, 2017
Expires: April 30, 2018
Type of Activity: Knowledge
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 60 minutes
This accredited activity has been designed for pharmacists.
HOW TO EARN CREDIT
During the period April 5, 2017 through April 30, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
To increase pharmacists' knowledge and competence in the pharmacotherapeutic treatment of patients with type 2 diabetes based on emerging evidence and current guideline recommendations.
Upon completion of this activity, participants should be better able to:
- Describe the results of key findings from prospective cardiovascular outcome trials (CVOTs) for DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors
- Select a glucose-lowering medication regimen for patients with, or at high risk for, cardiovascular disease
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer:
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC and Boehringer Ingelheim Pharmaceuticals Inc. and Lilly USA, LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.